Corcept Therapeutics Incorporated
CORT
$69.57
$0.751.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.71% | 30.93% | 39.94% | 39.67% | 33.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.71% | 30.93% | 39.94% | 39.67% | 33.04% |
| Cost of Revenue | 44.28% | 50.75% | 60.17% | 52.88% | 39.83% |
| Gross Profit | 25.45% | 30.65% | 39.67% | 39.49% | 32.95% |
| SG&A Expenses | 63.08% | 63.94% | 52.13% | 36.04% | 27.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.20% | 43.25% | 43.32% | 37.73% | 33.98% |
| Operating Income | -20.62% | -9.44% | 28.12% | 46.63% | 29.91% |
| Income Before Tax | -15.74% | -3.54% | 29.65% | 48.49% | 37.87% |
| Income Tax Expenses | -131.27% | -90.81% | 10.13% | 18.82% | 69.66% |
| Earnings from Continuing Operations | 6.09% | 13.53% | 33.04% | 55.19% | 33.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.09% | 13.53% | 33.04% | 55.19% | 33.15% |
| EBIT | -20.62% | -9.44% | 28.12% | 46.63% | 29.91% |
| EBITDA | -20.11% | -9.30% | 27.62% | 45.17% | 28.67% |
| EPS Basic | 4.46% | 11.77% | 32.10% | 56.08% | 36.72% |
| Normalized Basic EPS | -16.88% | -4.90% | 29.72% | 50.58% | 42.55% |
| EPS Diluted | -0.44% | 8.96% | 29.99% | 55.50% | 36.10% |
| Normalized Diluted EPS | -20.47% | -7.27% | 27.91% | 49.99% | 42.49% |
| Average Basic Shares Outstanding | 1.18% | 1.23% | -0.34% | -1.87% | -3.37% |
| Average Diluted Shares Outstanding | 6.62% | 4.93% | 1.42% | -1.48% | -3.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |